NWK Group’s Cellectis CLLS Stock Holding History

NWK Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,350	Closed	-$12K	–	257
2020 Q1	$12K	Buy	1,350 +150	+13%	+$2.24K	0.01%	137
2019 Q4	$21K	Buy	+1,200	New	+$16K	0.02%	146

Other funds holding CLLS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NWK Group's CLLS Position: Q2 2020 in Review

NWK Group sold out of Cellectis (CLLS) in Q2 2020, closing a stake of 1,350 shares — an estimated $12K sold.

NWK Group first reported a position in CLLS in Q4 2019 and held it in 2 quarters. The position peaked at $21K in Q4 2019. 79 funds tracked by Wall St. Rank hold CLLS as of Q2 2020.

NWK Group reported no remaining Cellectis position as of Q2 2020 after selling out during the quarter.
NWK Group sold 1,350 Cellectis shares in Q2 2020, an estimated $12K.
NWK Group first reported a position in Cellectis in Q4 2019 and held it in 2 quarters.
NWK Group's Cellectis position peaked at $21K in Q4 2019.
79 funds tracked by Wall St. Rank held Cellectis as of Q2 2020.

Based on NWK Group's 13F filing for Q2 2020, filed 13 Aug 2020.